Protagonist Therapeutics, Inc.
PTGX
$58.36
$2.173.86%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -69.38% | -65.34% | 448.54% | 221.61% | 223.50% |
Total Depreciation and Amortization | -15.07% | -12.64% | -12.59% | -3.89% | 0.75% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 31.29% | 24.22% | 15.09% | 13.75% | 6.84% |
Change in Net Operating Assets | -253.90% | 196.29% | -528.41% | 583.15% | 527.95% |
Cash from Operations | -82.92% | 632.15% | 362.19% | 293.80% | 297.19% |
Capital Expenditure | -252.53% | -97.15% | -122.50% | -61.21% | -65.79% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -62.98% | -844.46% | -671.37% | -1,418.29% | -260.67% |
Cash from Investing | -63.82% | -829.85% | -662.86% | -1,455.90% | -262.08% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -33.07% | -79.95% | -84.55% | -86.60% | -66.18% |
Repurchase of Common Stock | 20.17% | 62.25% | 21.98% | 21.98% | 22.18% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -33.24% | -80.10% | -84.83% | -86.89% | -66.43% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -255.52% | -173.34% | -246.73% | -227.92% | 4.44% |